At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunologic Effects of CpG ODN Administration to HIV Uninfected and HIV Infected Patients
In Brief
A Phase 2 clinical trial evaluating CpG7909 oligodeoxynucleotides (ODN) and Hepatitis B virus vaccine for HIV Infections and Hepatitis B. Completed, across 1 site.
Detailed Summary
The purpose of the study is to determine the safety of and immune response to a hepatitis B virus vaccine series given with a boosting agent, CpG7909 oligodeoxynucleotides (ODN), in HIV infected and HIV uninfected individuals who previously failed to develop a response to hepatitis B vaccine. Study hypothesis: Administration of CpG7909 ODN together with recombinant hepatitis B vaccine will result in increased frequency and magnitude of response to vaccine in individuals who have previously failed to mount a response to vaccination, and that in HIV infected subjects with detectable plasma viremia, it will lead to the enhancement of HIV-specific responses.